Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing: earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures gives cross-border investors faster access to Tokyo-listed disclosures.
This corporate disclosure from was processed by Pulse News Wire on February 6, 2026. It represents a primary source document for Japanese Earnings sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
Source disclosure: February 06, 2026 SHIN NIPPON BIOMEDICAL LABORATORIES,LTD. [2395.T] TOKYO, Feb 06 (Pulse News Wire) – SHIN NIPPON BIOMEDICAL LABORATORIES,LTD. (2395) has revised its FY2026/3 Full-Year consolidated earnings forecast. AI-translated content. 🟢 Confidence: High See terms • Original filing 💬 Help us improve translation quality Notice any errors in this article? Let us know with one click. ⚠️ Report an error Please sign in to report errors 🎁 Report
Source disclosure: February 06, 2026
SHIN NIPPON BIOMEDICAL LABORATORIES,LTD. [2395.T]
TOKYO, Feb 06 (Pulse News Wire) – SHIN NIPPON BIOMEDICAL LABORATORIES,LTD. (2395) has revised its FY2026/3 Full-Year consolidated earnings forecast.
AI-translated content. 🟢 Confidence: High See terms • Original filing